Verastem Oncology
在场
Verastem Oncology 是一家在股票代码 VSTM (US) 下上市的公司。
高管
查看带有其 21 名主要高管的组织结构图
Verastem Oncology 搜索最多的简介
- Dan Paterson, President and Chief Executive Officer
- Michael Kauffman, Lead Director
- Brian Stuglik, Director
高管在Verastem Oncology变化
- Mike Crowther已作为Chief Commercial and Business Strategy Officer加入公司 (新闻发布的2023十月27号).
- Dan Calkins 曾任 Vice President, Finance, 现升职为 Chief Financial Officer (新闻发布的2023十月27号).
创建提醒
跟踪 Verastem Oncology 的高管变动
生物技术
Verastem Oncology 拥有 2,275 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Bruker has announced the acquisition of NanoString Technologies (公布2024四月18号).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
- Nurix Therapeutics 刚刚宣布为 175 筹款数百万美元。 (公布2024四月13号).
生物技术 行业的其他推荐联系人
消息
Verastem Oncology 的最新新闻稿
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Verastem Inc.
- Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs | Verastem Inc.
- Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates | Verastem Inc.
- Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer | Verastem Inc.
- Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers | Verastem Inc.
- Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress | Verastem Inc.
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Verastem Inc.
- Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer | Verastem Inc.
- Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer | Verastem Inc.
- Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants | Verastem Inc.
- View more press releases Close
通过电子邮件
